Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review.

Eurich DT, McAlister FA, Blackburn DF, Majumdar SR, Tsuyuki RT, Varney J, Johnson JA.

BMJ. 2007 Sep 8;335(7618):497. Epub 2007 Aug 30. Review.

2.

Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients.

Eurich DT, Weir DL, Majumdar SR, Tsuyuki RT, Johnson JA, Tjosvold L, Vanderloo SE, McAlister FA.

Circ Heart Fail. 2013 May;6(3):395-402. doi: 10.1161/CIRCHEARTFAILURE.112.000162. Epub 2013 Mar 18. Review.

3.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
4.

Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study.

Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM.

Circulation. 2005 Feb 8;111(5):583-90.

5.

Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses.

Hemmingsen B, Christensen LL, Wetterslev J, Vaag A, Gluud C, Lund SS, Almdal T.

BMJ. 2012 Apr 19;344:e1771. doi: 10.1136/bmj.e1771. Review.

6.
7.

Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.

Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, Hughes RI, Khunti K, Wilkins MR, Majeed A, Elliott P.

BMJ. 2009 Dec 3;339:b4731. doi: 10.1136/bmj.b4731.

8.

Antihyperglycemic treatment in diabetics with coronary disease: increased metformin-associated mortality over a 5-year follow-up.

Fisman EZ, Tenenbaum A, Benderly M, Goldbourt U, Behar S, Motro M.

Cardiology. 1999;91(3):195-202.

PMID:
10516414
9.
10.

Neither diabetes nor glucose-lowering drugs are associated with mortality after noncardiac surgery in patients with coronary artery disease or heart failure.

Hanninen M, McAlister FA, Bakal JA, van Diepen S, Ezekowitz JA.

Can J Cardiol. 2013 Apr;29(4):423-8. doi: 10.1016/j.cjca.2012.07.004. Epub 2012 Sep 15.

PMID:
22985785
11.

Improved clinical outcomes associated with metformin in patients with diabetes and heart failure.

Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA.

Diabetes Care. 2005 Oct;28(10):2345-51.

PMID:
16186261
12.

Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and meta-analysis.

Singh S, Singh PP, Singh AG, Murad MH, McWilliams RR, Chari ST.

Am J Gastroenterol. 2013 Apr;108(4):510-9; quiz 520. doi: 10.1038/ajg.2013.7. Epub 2013 Feb 12. Review.

PMID:
23399556
13.

Oral antidiabetic drugs and regression from prediabetes to normoglycemia: a meta-analysis.

Phung OJ, Baker WL, Tongbram V, Bhardwaj A, Coleman CI.

Ann Pharmacother. 2012 Apr;46(4):469-76. doi: 10.1345/aph.1Q554. Epub 2012 Apr 3. Review.

PMID:
22474136
14.

Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project.

Inzucchi SE, Masoudi FA, Wang Y, Kosiborod M, Foody JM, Setaro JF, Havranek EP, Krumholz HM.

Diabetes Care. 2005 Jul;28(7):1680-9.

PMID:
15983320
15.

Type 2 diabetes mellitus and heart failure.

Choy CK, Rodgers JE, Nappi JM, Haines ST.

Pharmacotherapy. 2008 Feb;28(2):170-92. doi: 10.1592/phco.28.2.170. Review.

PMID:
18225964
16.

The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.

Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A, Zimmerman RS.

Acta Diabetol. 2009 Jun;46(2):145-54. doi: 10.1007/s00592-008-0090-3. Epub 2009 Feb 5.

PMID:
19194648
17.

Oral antidiabetic agents: current role in type 2 diabetes mellitus.

Krentz AJ, Bailey CJ.

Drugs. 2005;65(3):385-411. Review.

PMID:
15669880
18.

Non-insulin antidiabetic therapy in cardiac patients: current problems and future prospects.

Fisman EZ, Motro M, Tenenbaum A.

Adv Cardiol. 2008;45:154-70. doi: 10.1159/0000115193. Review.

PMID:
18230961
19.

Dobutamine for patients with severe heart failure: a systematic review and meta-analysis of randomised controlled trials.

Tacon CL, McCaffrey J, Delaney A.

Intensive Care Med. 2012 Mar;38(3):359-67. doi: 10.1007/s00134-011-2435-6. Epub 2011 Dec 8. Review.

PMID:
22160239
20.

Should antidiabetic treatment of type 2 diabetes in patients with heart failure differ from that in patients without?

Gitt AK, Halle M, Hanefeld M, Kellerer M, Marx N, Meier JJ, Schumm-Draeger PM, Bramlage P, Tschöpe D.

Eur J Heart Fail. 2012 Dec;14(12):1389-400. doi: 10.1093/eurjhf/hfs136. Epub 2012 Sep 13. Review.

Supplemental Content

Support Center